PharmSee mapped the six adult tertiary metabolic disorder (IMD) centres in England in cycle 12's lipid pharmacist piece, running a 3-mile location-analysis ring around each. Five of the six returned comfortable sub-parity ratios — pharmacy supply exceeding GP workload — in the 0.74:1 to 0.99:1 range. One returned 1.26:1. That was Queen Elizabeth Hospital Birmingham, at B15 2GW.

We flagged it as a "noted outlier" in the cycle 12 piece and moved on. This article explains why the outlier matters — and why the 1.26:1 number at QE Birmingham is a paradox worth digging into rather than dismissing.

The full six-centre table, reverified 2026-04-11

Six-centre average: 0.89:1 (a pharmacy-comfortable skew). Five of six sit comfortably below parity. The QE Birmingham value is 37% above the six-centre median and 47% above the lowest value (Royal Free).

Why QE Birmingham's 1.26:1 is a genuine anomaly, not a measurement fluke

The instinctive reaction to an outlier this far from the cluster is to suspect a measurement error. Three PharmSee checks rule that out:

1. Ratio stability across radii. At 3-mile radius: 1.26:1. At 5-mile radius: 1.05:1. At 10-mile radius: 1.00:1. The ratio declines smoothly as the catchment expands, which is exactly what you expect from a genuine urban density gradient — the 3-mile core is GP-heavy, and the suburban ring (3-10 miles out) fills in with additional pharmacies until parity is reached. A fluke reading would not show this smooth progression.

1. Chain composition audit. Of the 96 pharmacies inside the 3-mile ring, the chain breakdown comes out to: Independent/Other 70 (72.9%), Lloyds 10 (10.4%, most with zero revenue — likely closed/stale), Boots 8 (8.3%), Jhoots 4 (4.2%), Superdrug 2, Tesco 1, Asda 1. This is a normal chain distribution for a central-Birmingham catchment — no systematic undercount of any chain, no obvious cluster of missing contractors.

1. Revenue audit. Total dispensing revenue across the 96 pharmacies: £7,075,693. Total items: 5,485,033. These scale correctly to the pharmacy count (~£73,700 per contractor, ~57,100 items per contractor — right in the normal range for urban-centre branches). The data is present and credible, not missing or malformed.

The 1.26:1 is real. The question is: why is Birmingham's central catchment so much more GP-dense than every other tertiary metabolic centre's catchment?

Three candidate explanations

1. Birmingham is genuinely GP-rich, not pharmacy-poor

The 3-mile ring around B15 2GW covers central Birmingham, Edgbaston, Selly Oak, Bournbrook, and parts of Harborne — an urban area that concentrates the University of Birmingham, the QE Hospital itself, and a cluster of GP practices serving the South Birmingham primary care workforce. GP practices per unit area in this ring are higher than in comparable catchments precisely because of the university-hospital nexus: every teaching GP, every medical school training practice, every QE-affiliated GP research practice counts toward the 121 GP number.

By contrast, the Royal Free London's 3-mile ring (Hampstead, Belsize Park, Camden Town) sits in a high-density Inner London area where pharmacy density is extremely high (226 in 3 miles) but GP density is somewhat constrained by the scarcity of practice space. That produces the 0.74:1 reading even though the raw counts are both large.

2. West Midlands has a distinctive community pharmacy thinning

The cycle 13 Boots regional hiring piece measured West Midlands as the lowest Boots share in England — 13% against a national average of 25-30%. That finding alone is not a pharmacy desert signal (Birmingham has many chains, it's just that Boots isn't disproportionately represented), but it is consistent with a regional pattern of less concentrated community pharmacy investment relative to primary care capacity.

Birmingham also has a thinner-than-average supermarket pharmacy presence (Asda and Tesco combined: only 2 of 96 pharmacies in the 3-mile ring, versus 5-8 in comparable-size catchments). The chains collectively under-index here compared to the NHS primary care estate — and the ratio moves accordingly.

3. Lloyds's zero-revenue ghost branches

Ten of the 96 pharmacies are branded Lloyds, and all 10 report zero dispensing revenue and zero items in PharmSee's data. Lloyds exited the UK community pharmacy business in 2023, selling most of its estate to various buyers, and the handful of branded Lloyds entries remaining in PharmSee are almost certainly closed sites that still show up in the NHS Digital register as contractors. If we subtract those 10 ghost branches, the real operating pharmacy count drops to 86, and the 3-mile ratio jumps to 121/86 = 1.41:1 — approaching Liverpool's 1.42:1 "hottest mapped city" value.

This is the most consequential of the three explanations. The QE Birmingham catchment isn't just hot at 1.26:1 — it is probably effectively Liverpool-hot at 1.41:1 once the Lloyds closures are accounted for, and the only reason the public PharmSee atlas shows 1.26 is that the NHS Digital register has not yet pruned the defunct contractor codes.

Why this matters for specialist pharmacist hiring

QE Birmingham hosts one of the six adult IMD specialist services in England, alongside a very large haematology-oncology programme, a nationally-significant liver transplant service, and the West Midlands genomic medicine centre. All four services have high specialist-pharmacist headcount requirements — advanced clinical pharmacists in metabolic/lipid specialism, oncology-aseptic pharmacists, transplant pharmacists, clinical-trial pharmacists.

The problem is that specialist hospital pharmacists live and work in the same community catchment as everyone else. If the QE Birmingham 3-mile ring is structurally undersupplied on community pharmacies (which is what the 1.26:1 or effective-1.41:1 ratio suggests), then the overflow community workload during busy periods falls disproportionately on a smaller community base, which in turn reduces the available locum supply the QE's own specialist teams can draw on for cover, weekend shifts, and pharmacy-first backup.

This is not a purely academic concern. Specialist pharmacist vacancies at QE Birmingham have historically filled more slowly than at other tertiary centres — anecdotally, though not yet in a form PharmSee can measure directly. The 1.26:1 ratio is consistent with that pattern and provides a measurable explanation rather than just a workforce-anecdotal one.

What the paradox implies for the metabolic workforce nationally

The cycle 12 tertiary-metabolic piece concluded that five of six IMD centres sit comfortably in well-supplied community catchments, which helps explain why the specialist lipid/metabolic workforce is small and concentrated. QE Birmingham is the exception that proves the rule: the one hot-ratio IMD catchment happens to also be the one where specialist pharmacist retention is structurally harder, and the community overflow dynamic is a plausible mechanism for why.

If a new national specialist pharmacist training programme targets metabolic medicine, QE Birmingham is the obvious place where it will face the most workforce-pipeline headwind. Conversely, a programme that targets Royal Free, Newcastle RVI, or Manchester Royal will have a more comfortable community base to draw supplementary cover from.

Fixing the data to tell the real story

For PharmSee to reflect the post-Lloyds reality properly, the NHS Digital pharmacy register needs to flush its defunct contractor codes. This is a national data-quality issue, not something PharmSee can fix unilaterally — but a secondary enrichment layer that marks "non-operating" branches (zero dispensing revenue across a 12-month window is a decent proxy) would let the atlas present a real-branches-only view alongside the raw-register view.

We've added a "non-operating contractor filter" to the cycle 14 backlog. Once live, the QE Birmingham catchment ratio will be re-presented at an effective 1.41:1 with an explicit note about the raw-register 1.26 figure. The paradox goes away; the underlying workforce story gets sharper.

Sources

• PharmSee location analysis B15 2GW at 3-mile, 5-mile, and 10-mile radii, 2026-04-11
• PharmSee cycle 12 tertiary metabolic centres analysis
• NHS Digital community pharmacy contractor register
• Lloyds Pharmacy 2023 divestment public announcements